Apellis Pharmaceuticals, Inc.

DB:1JK Stock Report

Market Cap: €3.6b

Apellis Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

DB:1JK Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
22 Jan 25Sell€40,779Mark DelongIndividual1,396€29.21
22 Jan 25Sell€37,712Jeffrey EiseleIndividual1,291€29.21
22 Jan 25Sell€32,016James ChopasIndividual1,096€29.21
22 Jan 25Sell€115,327Pascal DeschateletsIndividual3,948€29.21
22 Jan 25Sell€90,205Timothy SullivanIndividual3,088€29.21
22 Jan 25Sell€115,327Nur NicholsonIndividual3,948€29.21
22 Jan 25Sell€51,149Karen LewisIndividual1,751€29.21
22 Jan 25Sell€395,845Cedric FrancoisIndividual13,551€29.21
22 Jan 25Sell€97,070David WatsonIndividual3,323€29.21
22 Jan 25Sell€97,070Adam TownsendIndividual3,323€29.21
21 Jan 25Sell€20,589James ChopasIndividual715€28.80
17 Jan 25Sell€36,126Karen LewisIndividual1,241€29.11
17 Jan 25Sell€53,942Caroline BaumalIndividual1,853€29.11
17 Jan 25Sell€35,951Mark DelongIndividual1,235€29.11
17 Jan 25Sell€174,866Cedric FrancoisIndividual6,007€29.11
17 Jan 25Sell€21,833Pascal DeschateletsIndividual750€29.11
17 Jan 25Sell€62,442Nur NicholsonIndividual2,145€29.11
17 Jan 25Sell€64,072Adam TownsendIndividual2,201€29.11
17 Jan 25Sell€50,361Timothy SullivanIndividual1,730€29.11
17 Jan 25Sell€64,072David WatsonIndividual2,201€29.11
13 Jan 25Sell€44,995Mark DelongIndividual1,599€28.14
13 Jan 25Sell€7,429Jeffrey EiseleIndividual264€28.14
13 Jan 25Sell€64,383Pascal DeschateletsIndividual2,288€28.14
13 Jan 25Sell€175,788Cedric FrancoisIndividual6,247€28.14
13 Jan 25Sell€44,995Karen LewisIndividual1,599€28.14
13 Jan 25Sell€74,063Nur NicholsonIndividual2,632€28.14
13 Jan 25Sell€139,713David WatsonIndividual4,965€28.14
13 Jan 25Sell€75,555Adam TownsendIndividual2,685€28.14
13 Jan 25Sell€22,033James ChopasIndividual783€28.14
06 Jan 25Sell€91,635Caroline BaumalIndividual2,816€32.54
23 Dec 24Sell€2,005Jeffrey EiseleIndividual63€31.83
11 Dec 24Sell€163,250David WatsonIndividual5,000€32.65
16 Sep 24Sell€6,249James ChopasIndividual192€32.55
03 Sep 24Sell€19,674James ChopasIndividual550€35.77
19 Mar 24Sell€983,563Epidarex CapitalCompany18,681€52.65
18 Mar 24Sell€518,813Mark DelongIndividual9,913€52.34
15 Mar 24Sell€9,541James ChopasIndividual184€51.85
13 Mar 24Sell€590,102Nur NicholsonIndividual11,220€53.12
12 Feb 24Sell€37,556Mark DelongIndividual597€62.91
12 Feb 24Sell€90,021Timothy SullivanIndividual1,431€62.91
12 Feb 24Sell€72,218Adam TownsendIndividual1,148€62.91
12 Feb 24Sell€49,131David WatsonIndividual781€62.91
12 Feb 24Sell€249,242Cedric FrancoisIndividual3,962€62.91
12 Feb 24Sell€72,218Pascal DeschateletsIndividual1,148€62.91
29 Jan 24Sell€21,787Mark DelongIndividual367€59.37
29 Jan 24Sell€16,563Jeffrey EiseleIndividual279€59.37
29 Jan 24Sell€168,778Cedric FrancoisIndividual2,843€59.37
29 Jan 24Sell€51,886Pascal DeschateletsIndividual874€59.37
29 Jan 24Sell€53,786Adam TownsendIndividual906€59.37
29 Jan 24Sell€53,786David WatsonIndividual906€59.37
29 Jan 24Sell€49,571Nur NicholsonIndividual835€59.37
29 Jan 24Sell€53,786Timothy SullivanIndividual906€59.37
29 Jan 24Sell€21,787Karen LewisIndividual367€59.37

Insider Trading Volume

Insider Buying: 1JK insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of 1JK?
Owner TypeNumber of SharesOwnership Percentage
State or Government45,6250.0334%
Individual Insiders4,388,3003.22%
VC/PE Firms12,806,3429.38%
Hedge Funds23,001,95416.9%
Institutions96,220,01670.5%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 91.49% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
12.5%
Wellington Management Group LLP
15,566,969€456.4m-5.01%0.07%
10.3%
The Morningside Group Limited
12,806,342€375.4m0%28.62%
9.56%
EcoR1 Capital, LLC
11,890,843€348.6m2.44%13.52%
8.93%
Avoro Capital Advisors LLC
11,111,111€325.7m0%4.7%
7.89%
The Vanguard Group, Inc.
9,815,575€287.8m0.06%no data
4.98%
BlackRock, Inc.
6,192,368€181.5m6.85%no data
4.82%
Deep Track Capital, LP
6,000,000€175.9m36.3%5.59%
3.25%
State Street Global Advisors, Inc.
4,040,861€118.5m-2.55%no data
3.06%
JP Morgan Asset Management
3,808,257€111.6m21.6%0.01%
2.7%
T. Rowe Price Group, Inc.
3,363,728€98.6m-36.8%0.01%
2.64%
Morgan Stanley, Investment Banking and Brokerage Investments
3,281,668€96.2m62.8%0.01%
2.51%
Braidwell LP
3,125,183€91.6m411%4.17%
2.42%
Octagon Capital Advisors LP
3,006,980€88.2m4.38%14.84%
2.33%
FMR LLC
2,896,894€84.9m-12.2%no data
1.74%
Artal Group S.A.
2,167,224€63.5m47.7%1.99%
1.46%
Jennison Associates LLC
1,821,115€53.4m-49.3%0.03%
1.46%
Geode Capital Management, LLC
1,810,526€53.1m1.26%no data
1.41%
Cedric Francois
1,748,023€51.2m-4.7%no data
1.39%
Tavistock Life Sciences
1,726,000€50.6m0%3.82%
1.38%
Deutsche Asset & Wealth Management
1,722,372€50.5m-5.34%0.01%
1.09%
Fiera Capital Corporation
1,354,469€39.7m-3.33%0.09%
1.02%
OrbiMed Advisors LLC
1,270,400€37.2m-2.49%0.54%
0.9%
Pascal Deschatelets
1,119,057€32.8m0.46%no data
0.87%
Polar Capital Holdings Plc
1,082,000€31.7m0.24%0.11%
0.87%
Norges Bank Investment Management
1,079,605€31.7m0%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/24 01:03
End of Day Share Price 2025/01/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Apellis Pharmaceuticals, Inc. is covered by 34 analysts. 21 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Colleen KusyBaird
Michael UlzBaird
Ishan MajumdarBaptista Research